Replicel Life Sciences Inc V.RP

Alternate Symbol(s): REPCF

Technology Scientific & Technical Instruments

RepliCel Life Sciences Inc. is a Canada-based regenerative medicine company. The Company is focused on developing cell therapies for aesthetic and orthopedic conditions, including aging/sun-damaged skin, pattern baldness, and chronic tendon degeneration. The Company’s cell therapy product pipeline is comprised of RCT-01 for tendon repair, RCS-01 for skin rejuvenation, and RCH-01 for hair restoration. RCH-01 is an autologous cell therapy utilizing dermal sheath cup (DSC) cells isolated from the hair follicle to treat androgenetic alopecia. RCS-01 is an autologous cell therapy utilizing non-bulbar dermal sheath (NBDS) cells, a type of fibroblast cell isolated from the hair follicle to repair and regenerate tissue. RCT-01 provides a source of collagen expressing cells to the site of injury, addressing the underlying cause of tendinosis. It has also developed an injection device, DermaPrecise, which improves the administration of its cell therapy products and certain other injectables.

TSXV:RP - Post by User

Replicel Life Sciences Inc > Twitter (X)

<< Previous

Bullboard Posts

Next >>

Comment by Genie29jon Jul 28, 2023 9:24pm

117 Views

Post# 35562782

RE:RE:RE:RE:RE:RE:RE:Twitter (X)

Come Labor Day we will know if Replicel is alive and well, or if we will all be having a pity party / faiwell party.

I am really praying for no less than $5 per share at the current outstanding share amount.

<< Previous

Bullboard Posts

Next >>

Investors eye Australian gold mining projects amid promising developments